PRLB — Proto Labs, Inc.

Summary of Proto Labs Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $136.5 million, up 11% year-over-year in constant currencies, marking a record for the company.
• Full Year Revenue: $533.1 million, a 5.7% increase in constant currencies.
• US Revenue Growth: 9.1% year-over-year; CNC machining revenue grew 35% in Q4.
• Non-GAAP Gross Margin: Q4 at 44.8%, up 140 basis points year-over-year; Full year at 45.1%.
• Non-GAAP EPS: $0.44 for Q4, up from $0.38 year-over-year; Full year at $1.66, up 3 cents year-over-year.
• Cash Flow: Generated $74.5 million from operations in 2025; $142.4 million in cash and investments with zero debt.

2. Strategic Updates and Business Highlights

• Customer Experience: Focus on enhancing customer engagement through a unified e-commerce platform and improved service delivery.
• Innovation: Plans to accelerate product launches, including advanced CNC machining and expanded metal 3D printing capabilities.
• Production Expansion: Achieved ISO 13485 certification for injection molding, enabling entry into medical device production.
• Operational Efficiency: Initiatives to improve productivity and reduce costs, including a new global capability center in India to enhance innovation and engineering capabilities.
• Market Focus: Strong demand in aerospace, defense, and data centers, with a strategic emphasis on these growth sectors.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected growth of 6-8%, with Q1 revenue guidance between $130 million and $138 million.
• Long-Term Goals: Aiming for sustained double-digit revenue growth and a path to $1 billion in annual revenue over time.
• Earnings Guidance: Q1 2026 non-GAAP EPS expected between $0.36 and $0.44.

4. Bad News, Challenges, or Points of Concern

• European Market Decline: Revenue in Europe declined 7% year-over-year, attributed to macroeconomic uncertainty and internal complexities.
• Injection Molding Weakness: Injection molding revenue declined 1.9% due to lower prototyping demand, impacting overall growth.
• Network Gross Margin: Declined to 31%, down 190 basis points year-over-year, primarily due to tariff-related inefficiencies.
• Visibility on Growth: While optimistic about future growth, management acknowledged the unpredictability of customer project timing, particularly in Q1.

5. Notable Q&A Insights

• Sequential Growth: Management noted that Q4's sequential revenue growth was the first since 2017, but Q1 typically sees a normalization post-holidays.
• Focus on Revenue per Customer: Revenue per contact increased 23% in Q4, indicating a strategy to deepen existing customer relationships rather than solely expanding the customer base.
• Defense Supply Chain: Management highlighted good exposure to aerospace and defense markets but refrained from discussing specific government initiatives related to reshoring.
• Injection Molding Outlook: The company is transitioning towards production in injection molding, with pilot programs underway with medical device manufacturers.

Overall, Proto Labs demonstrated strong financial performance in 2025, with strategic initiatives aimed at enhancing customer experience and expanding production capabilities, while also addressing challenges in the European market and injection molding segment.